Search Result

Results for "

Myc-Max

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Myc (10) Apoptosis (2) Autophagy (3) PARP (1) PROTACs (1)
By Research Areas:	Cancer (12)

Inhibitors & Agonists

Screening Libraries

Targets Recommended: c-Myc

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147291

VPC-70063	c-Myc PARP Apoptosis	Cancer
VPC-70063 is a potent *Myc-Max* inhibitor with an IC₅₀ value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer .

HY-122683

sAJM589 1 Publications Verification	c-Myc	Cancer
sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC₅₀ of 1.8 μM .

HY-150259

MDEG-541	PROTACs c-Myc	Cancer
MDEG-541 is a potent *MYC-MAX* degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein .

HY-134975

NY2267	c-Myc	Cancer
NY2267 is a disruptor of Myc-Max interaction, with an IC₅₀ of 36.5 μM. NY2267 inhibits Myc- and Jun-induced transcriptional activation .

HY-124675

MYCMI-6 1 Publications Verification NSC354961	c-Myc Apoptosis	Cancer
MYCMI-6 (NSC354961) is a potent and selective endogenous *MYC:MAX* protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a K_d of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC₅₀<0.5 μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis .

HY-100996

10074-G5 2 Publications Verification	c-Myc Autophagy	Cancer
10074-G5 is an inhibitor of *c-Myc-Max* dimerization with an IC₅₀ of 146 μM.

HY-12702

10058-F4 Maximum Cited Publications 38 Publications Verification	c-Myc Autophagy	Cancer
10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

HY-125978

JY-3-094	c-Myc	Cancer
JY-3-094 is a Myc inhibitor that inhibits *Myc-Max* heterodimer formation (IC₅₀: 33 μM) .

HY-125636

Mycro1	Others	Cancer
Mycro1 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC₅₀ value of 30 μM for the inhibition of Myc/Max DNA binding activity. Mycro1 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation .

HY-126979

Mycro2	Others	Cancer
Mycro2 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC₅₀ value of 23 μM for the inhibition of Myc/Max DNA binding activity. Mycro2 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation .

HY-12703

KSI-3716 1 Publications Verification	c-Myc Autophagy	Cancer
KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer .

HY-144878

VPC-70619 2 Publications Verification	c-Myc	Cancer
VPC-70619 is a potent, orally active N-Myc inhibitor. VPC-70619 blocks the N-Myc-Max heterocomplex from binding to DNA E-boxes and demonstrated strong inhibition activity against N-Myc-dependent cell lines as well as high bioavailability in both oral and intraperitoneal administration .

Cat. No.	Product Name

HY-L109

Protein-protein Interaction Inhibitor Library	600 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 600 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Protein-protein Interaction Inhibitor Library

600 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 600 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.